PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-95.21%
Revenue decline while CRVO shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
31.39%
Cost growth of 31.39% while CRVO maintains flat costs. Bruce Berkowitz would investigate efficiency gap.
-116.81%
Gross profit decline while CRVO shows 0.00% growth. Joel Greenblatt would examine competitive position.
-451.18%
Margin decline while CRVO shows 0.00% expansion. Joel Greenblatt would examine competitive position.
6.71%
R&D growth while CRVO reduces spending. John Neff would investigate strategic advantage.
86.34%
G&A change of 86.34% while CRVO maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
29.34%
Operating expenses growth while CRVO reduces costs. John Neff would investigate differences.
29.34%
Total costs growth while CRVO reduces costs. John Neff would investigate differences.
-100.00%
Interest expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
31.39%
D&A change of 31.39% while CRVO maintains D&A. Bruce Berkowitz would investigate efficiency.
-52.58%
EBITDA decline while CRVO shows 6.20% growth. Joel Greenblatt would examine position.
-3087.14%
EBITDA margin decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
-52.01%
Operating income decline while CRVO shows 6.78% growth. Joel Greenblatt would examine position.
-3075.40%
Operating margin decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
137.14%
Other expenses growth 1.25-1.5x CRVO's 99.14%. Martin Whitman would scrutinize cost items.
-51.43%
Pre-tax income decline while CRVO shows 7.43% growth. Joel Greenblatt would examine position.
-3063.27%
Pre-tax margin decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
100.00%
Tax expense change of 100.00% while CRVO maintains burden. Bruce Berkowitz would investigate strategy.
-52.47%
Net income decline while CRVO shows 7.43% growth. Joel Greenblatt would examine position.
-3085.00%
Net margin decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
-43.48%
EPS decline while CRVO shows 7.51% growth. Joel Greenblatt would examine position.
-43.48%
Diluted EPS decline while CRVO shows 7.51% growth. Joel Greenblatt would examine position.
7.17%
Share count reduction below 50% of CRVO's 0.02%. Michael Burry would check for concerns.
7.17%
Diluted share reduction below 50% of CRVO's 0.02%. Michael Burry would check for concerns.